The analysis indicates that CVS Health has been ranked as a buy candidate since August 14, 2025, with a score of 1.09. The stock has shown a gain of 15% over 40 days, resulting in a 0.38% average daily gain. It's currently in a short-term upward trend, and the analysis suggests a potential 30% change in the next three months, estimating a return range between 26% and 34%. Over a 12-month period, a 34% change is projected, resulting in a price of between 79.94 and 104.28. The stock closed at 76.74 on the last trading day, down 0.247%, with a fluctuation of 1.48%. Trading volume decreased, the stock's current price 3.09% below its 52-week high, analyst ratings are generally positive, leading the report to deem its current price undervalued and a worthwhile buy.